An interventional study of SVL and SVL with passive red-light emission in Myopia, sponsored by Essilor International. Recruiting at 1 site in Singapore. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myopia by EssilorLuxottica — 14 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.
Among the 28 studies in Myopia by EssilorLuxottica, this one is the 20th largest by planned enrollment, is one of 9 that started in 2025, is one of 28 with no phase, reaches primary completion later than 12 of the 18 other live ones, and was the 10th registered.
1,160 studies on the registry are indexed under Myopia; 226 are open to participants now.
Browse Myopia studies →14 of the 28 studies in Myopia by EssilorLuxottica are open now, in 5 countries. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Essilor International · Sites in China
Ages 6–12
By country, each count listing its studies:
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2025.
This study's planned enrollment of 35 is below the median of 79 across 924 interventional studies indexed under Myopia.
Median enrollment 52 across the 28 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
6 of the studies in Myopia by EssilorLuxottica that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT06850168Essilor InternationalClinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression | 2027-10 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Myopia by EssilorLuxottica, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this exploratory clinical trial is to evaluate the efficacy and safety of a test spectacle lens (standard single vision lens (SVL) during first year, and standard myopia control lens (MCL) in second year), designed with passive red-light emission, for the control of myopia progression in myopic children age 6 to 11 years old, both male and female, with no systemic or ocular anomalies. The main question it aims to answer is:
Does the test spectacle lens designed with passive red-light emission provide significant myopia control effect to children?
Researchers will compare the standard SVL designed with passive red-light emission to SVL (first year) and MCL designed with passive red-light emission to MCL (second year) to see if the test spectacle lens work to slow down myopia progression.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Year 1) OD: SVL with passive red-light emission; OS: SVL (Year 2) OD: MCL; OS: MCL with passive red-light emission
Device: SVL · Device: SVL with passive red-light emission · Device: MCL · Device: MCL with passive red-light emission
(Year 1) OD: SVL; OS: SVL with passive red-light emission (Year 2) OD: MCL with passive red-light emission; OS: MCL
Device: SVL · Device: SVL with passive red-light emission · Device: MCL · Device: MCL with passive red-light emission
Dispensed to one eye in Year 1
Dispensed to the contralateral eye in Year 1.
Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).
Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).
Change in Axial Length
Time frame: From baseline to 12 months
Change in Axial Length
Time frame: From 12 months to 24 months
Change in Spherical Equivalent Refraction
Time frame: From baseline to 12 months
Change in Spherical Equivalent Refraction
Time frame: From 12 months to 24 months
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.
Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 28 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.